Nuvation Bio vs Regenxbio
Regenxbio is the larger business, with $170m of revenue in fiscal 2025 against $62.9m for Nuvation Bio (2.7 times as much). Nuvation Bio grew faster (699.0% against 104.5%). Regenxbio kept more of each dollar of sales as profit: a net margin of -113.8% against -325.3%. Regenxbio carries less debt relative to equity (0.0% against 17.3%).
| Latest fiscal year | Nuvation BioNUVB, 2025 | RegenxbioRGNX, 2025 |
|---|---|---|
| Revenue | $62.9m | $170m |
| Revenue growth | 699.0% | 104.5% |
| Net income | −$205m | −$194m |
| Operating margin | -338.7% | -94.6% |
| Net margin | -325.3% | -113.8% |
| Return on equity | -53.2% | -107.0% |
| Free cash flow | −$181m | −$126m |
| Cash | $164m | $34.5m |
| Total debt | $52.9m | $0 |
| Debt to equity | 17.3% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 298 | 371 |
| Market value | $1.61bn | $408m |
| Price vs our value range | — | — |
| Moat score | — | 19 (Weak) |
| Insider trades, 12 months | 1 buys, 16 sales | 2 buys, 5 sales |